During the investigation, alliance investigators evaluated 218 properties reclaimed by Wells Fargo.
Both trials were 1-year, multicenter, open-label investigations in which investigators evaluated the safety and efficacy of two injections spaced 6 months apart and found high efficacy rates and low rates of serious adverse events (SAEs).
In April 2001, a group of spinal surgeons, including several investigators, evaluated the radiographs of the investigational patients in the clinical trial.
In a second step, the same investigators evaluated the remaining studies in their entirety.
In addition, the same investigators evaluated the adequate procurement of transthoracic echocardiographic windows for estimation of the stroke volume.
In order to reduce the radiation dose, investigators evaluated specific low-dose dual-energy protocols as being within the range of single-energy acquisitions [16].
The investigators evaluated almost 2,000 young women in France, the Netherlands and the United Kingdom.
That is, separate investigators evaluated either mepps or embryo genotypes.
The investigators evaluated neuropathy using a targeted history composed of structured validated questions designed to elicit symptoms of distal sensory loss or pain.
Two independent investigators evaluated all staining.
Two investigators evaluated results in blinded manner.
